Adagene Inc. (ADAG)
| Market Cap | 241.83M +224.9% |
| Revenue (ttm) | 7.67M +7,332.8% |
| Net Income | -17.61M |
| EPS | -0.38 |
| Shares Out | 66.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 195,012 |
| Open | 3.670 |
| Previous Close | 3.820 |
| Day's Range | 3.530 - 3.815 |
| 52-Week Range | 1.300 - 4.750 |
| Beta | 0.59 |
| Analysts | Strong Buy |
| Price Target | 8.25 (+125.41%) |
| Earnings Date | Apr 1, 2026 |
About ADAG
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 ... [Read more]
Financial Performance
In 2025, Adagene's revenue was $7.67 million, an increase of 7332.76% compared to the previous year's $103,204. Losses were -$17.61 million, -47.32% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ADAG stock is "Strong Buy." The 12-month stock price target is $8.25, which is an increase of 125.41% from the latest price.
News
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively...
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and developm...
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development of novel ant...
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
Dose-Dependent Efficacy Results : As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement o...
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, ...
Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based the...
Adagene Transcript: Leerink Global Healthcare Conference 2026
ADG126 demonstrates strong efficacy and safety in late-line MSS CRC, with higher doses yielding better response rates and durability. Strategic collaborations and pipeline expansion target additional indications and novel combinations, with upcoming data expected to further validate the program.
Adagene Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
ADG126, a masked anti-CTLA-4 antibody, is showing promising efficacy and safety in late-line MSS-CRC without liver metastases, with response rates up to 29% and median survival of 19–20 months. Strategic collaborations, notably with Sanofi, support ongoing trials and future expansion.
Adagene to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ther...
Adagene Provides Business Update and 2026 Objectives
Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December 31,...
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc...
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) and Third Arc Bio, Inc. (“Third Arc Bio”), today announced a licensing agre...
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Unde...
Adagene Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
ADG126, an AI-engineered masked anti-CTLA-4 antibody, shows strong efficacy and safety in MSS-CRC non-liver metastasis, with a 29% response rate and 19-month median survival. A $25M SNOWPEA investment extends cash runway to 2027 and supports global phase 2 trials, while regulatory and strategic partnerships drive expansion.
Adagene Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The event highlighted progress on a novel anti-CTLA-4 antibody, ADG126, with strong safety and efficacy data, expanded collaboration with Sanofi, and upcoming clinical milestones. Financial runway extends into 2027, with key data updates expected in early 2026.
Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based the...
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announc...
Adagene to Participate in Two Investor Conferences in September
SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ther...
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adage...
Adagene announces up to $25 million strategic investment from Sanofi
- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug
Adagene Transcript: Jefferies Global Healthcare Conference 2025
ADG126 shows a 29% confirmed response rate and favorable safety in late-line MSS colorectal cancer, with ongoing regulatory discussions and expansion into broader patient groups and new indications. Key updates and partnership opportunities are expected in the coming year.